DXd then infiltrates through the cell membrane to adjacent tumor cells causing DNA damage and cell death, independent of their HER2 status; therefore T-DXd exhibits clinical efficacy amongst heterogenous HER2 tumors [24]. Here, ERBB2 is linked to neoplasm.